Literature DB >> 8883266

Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation.

P J van Genderen1, I S Lucas, R van Strik, V D Vuzevski, F J Prins, H H van Vliet, J J Michiels.   

Abstract

Erythromelalgia, a characteristic aspirin-responsive microvascular thrombotic complication in essential thrombocythemia (ET), may develop despite oral anticoagulant treatment or treatment with heparin, suggesting that the generation of thrombin is not a prerequisite for its development. To study this, a cross-sectional comparison of the plasma levels of thrombomodulin (TM), platelet factor 4 (PF4), beta-thromboglobulin (beta-TG), prothrombin fragment 1 + 2 (F1 + 2) and total degradation products of fibrin(ogen) (TDP) was made between 5 ET patients suffering from erythromelalgia, 16 asymptomatic ET patients and 20 control subjects, and after treatment with aspirin, respectively. Furthermore, 2 ET patients with a history of erythromelalgia were studied at regular time intervals after discontinuation of aspirin until erythromelalgia recurred. As compared with asymptomatic ET patients and control subjects erythromelalgia was characterized by significantly higher beta-TG and TM levels but no significant differences were detected in either F1 + 2 or TDP levels. Treatment of erythromelalgia with aspirin resulted in disappearance of erythromelalgic signs and symptoms, which was paralleled by a significant decrease of beta-TG and TM levels. Histopathologic and immunohistochemical analysis of biopsies derived from erythromelalgic skin areas of 2 ET patients showed that erythromelalgic thrombi stained positively for von Willebrand factor opposed to only a weak fibrin staining. Our data suggest that erythromelalgia is caused by the intravascular activation and aggregation of platelets with subsequent sludging or occlusion of the acral arterial microvasculature. The generation of thrombin appears not to be essential for the formation of these platelet thrombi, thereby giving a plausible explanation for the inefficacy of coumadin derivatives and heparin in the prevention and treatment of erythromelalgia in essential thrombocythemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883266

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Left main coronary thrombosis with essential thrombocythemia.

Authors:  Zekeriya Nurkalem; Nevzat Uslu; Sevket Gorgulu; Mehmet Eren
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

2.  Acute lower limb ischemia in a patient with aortic thrombus and essential thrombocytosis.

Authors:  P Caridad Morata Barrado; E Blanco Cañibano; B García Fresnillo; M Guerra Requena
Journal:  Int J Hematol       Date:  2009-08-11       Impact factor: 2.490

3.  Essential Thrombocythemia Complicated by Occlusive Thrombosis of the Abdominal Aorta.

Authors:  Jamie Geringer; Joshua Fenderson; Michael Osswald
Journal:  Case Rep Hematol       Date:  2019-03-26

4.  Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.

Authors:  Marina Karakantza; Nikolaos C Giannakoulas; Panagiotis Zikos; George Sakellaropoulos; Alexandra Kouraklis; Anthi Aktypi; Ioannis C Metallinos; Eleni Theodori; Nicholas C Zoumbos; Alice Maniatis
Journal:  Int J Hematol       Date:  2004-04       Impact factor: 2.490

Review 5.  Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.

Authors:  Douglas Tremblay; Abdulraheem Yacoub; Ronald Hoffman
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-26       Impact factor: 3.722

Review 6.  Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.

Authors:  Cecilia P Marin Oyarzún; Paula G Heller
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

7.  Thiol-disulphide Homeostasis in Essential Thrombocythemia Patients.

Authors:  Aysun Şentürk Yıkılmaz; Şule Mine Bakanay; Sema Akinci; Murat Alisik; Özcan Erel; İmdat Dilek
Journal:  J Med Biochem       Date:  2019-07-30       Impact factor: 3.402

8.  Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia.

Authors:  Monica Sacco; Paola Ranalli; Stefano Lancellotti; Giovanna Petrucci; Alfredo Dragani; Bianca Rocca; Raimondo De Cristofaro
Journal:  Res Pract Thromb Haemost       Date:  2020-02-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.